Mineralys Therapeutics, Inc.
MLYSNASDAQHealthcare● Active
$22.50
$-1.19(-5.02%)
Market Cap$1.5B
P/E Ratio—
52W High$47.65
52W Low$12.59
Mineralys Therapeutics, Inc. (MLYS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MLYS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.15B) | ($0.18B) | ($0.07B) | ($0.03B) | ($0.02B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | $0.01B | ($0.01B) | $0.00B | $0.00B |
| Net Cash from Operations | ($0.14B) | ($0.17B) | ($0.08B) | ($0.03B) | ($0.01B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | ($0.81B) | ($0.37B) | ($0.35B) | ($0.07B) | $0.00B |
| Sales of Investments | $0.42B | $0.49B | $0.19B | $0.05B | $0.00B |
| Net Cash from Investing | ($0.39B) | $0.11B | ($0.16B) | ($0.02B) | $0.00B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.59B | $0.12B | $0.20B | $0.13B | $0.02B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.14B) | ($0.17B) | ($0.08B) | ($0.03B) | ($0.01B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Mineralys Therapeutics, Inc. data
About Mineralys Therapeutics, Inc. (MLYS) Cash Flow Statement
Mineralys Therapeutics, Inc. generated operating cash flow of ($0.14B) and free cash flow of ($0.14B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
MLYS · 4 questionsMineralys Therapeutics, Inc. generated free cash flow of ($0.14B) for 2025, up 14.4% year-over-year.
MLYS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10